BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 20687221)

  • 21. Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer.
    Morote J; Morin JP; Orsola A; Abascal JM; Salvador C; Trilla E; Raventos CX; Cecchini L; Encabo G; Reventos J
    Urology; 2007 Mar; 69(3):500-4. PubMed ID: 17382153
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study.
    Zapatero A; Valcárcel F; Calvo FA; Algás R; Béjar A; Maldonado J; Villá S
    J Clin Oncol; 2005 Sep; 23(27):6561-8. PubMed ID: 16170164
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with nonmetastatic prostate cancer.
    Joly F; Alibhai SM; Galica J; Park A; Yi QL; Wagner L; Tannock IF
    J Urol; 2006 Dec; 176(6 Pt 1):2443-7. PubMed ID: 17085125
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Health-related quality of life among patients with metastatic prostate cancer.
    Albertsen PC; Aaronson NK; Muller MJ; Keller SD; Ware JE
    Urology; 1997 Feb; 49(2):207-16; discussion 216-7. PubMed ID: 9037282
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Androgen deprivation in veterans with prostate cancer: implications for skeletal health.
    Wilcox A; Carnes ML; Moon TD; Tobias R; Baade H; Stamos E; Elliott ME
    Ann Pharmacother; 2006 Dec; 40(12):2107-14. PubMed ID: 17132807
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer.
    Galvão DA; Spry NA; Taaffe DR; Newton RU; Stanley J; Shannon T; Rowling C; Prince R
    BJU Int; 2008 Jul; 102(1):44-7. PubMed ID: 18336606
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Survival benefit associated with adjuvant androgen deprivation therapy combined with radiotherapy for high- and low-risk patients with nonmetastatic prostate cancer.
    Zeliadt SB; Potosky AL; Penson DF; Etzioni R
    Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):395-402. PubMed ID: 16904843
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II trial of radiation dose escalation with conformal external beam radiotherapy and high-dose-rate brachytherapy combined with long-term androgen suppression in unfavorable prostate cancer: feasibility report.
    Valero J; Cambeiro M; Galán C; Teijeira M; Romero P; Zudaire J; Moreno M; Ciérvide R; Aristu JJ; Martínez-Monge R
    Int J Radiat Oncol Biol Phys; 2010 Feb; 76(2):386-92. PubMed ID: 19427741
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The use of treatments for erectile dysfunction among survivors of prostate carcinoma.
    Schover LR; Fouladi RT; Warneke CL; Neese L; Klein EA; Zippe C; Kupelian PA
    Cancer; 2002 Dec; 95(11):2397-407. PubMed ID: 12436448
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Circulating inflammatory cytokine expression in men with prostate cancer undergoing androgen deprivation therapy.
    Maggio M; Blackford A; Taub D; Carducci M; Ble A; Metter EJ; Braga-Basaria M; Dobs A; Basaria S
    J Androl; 2006; 27(6):725-8. PubMed ID: 16775253
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
    Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
    Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy.
    Krupski TL; Smith MR; Lee WC; Pashos CL; Brandman J; Wang Q; Botteman M; Litwin MS
    Cancer; 2004 Aug; 101(3):541-9. PubMed ID: 15274067
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
    Miller N; Smolkin ME; Bissonette E; Theodorescu D
    Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quality of life, self-esteem, fatigue, and sexual function in young men after cancer: a controlled cross-sectional study.
    Greenfield DM; Walters SJ; Coleman RE; Hancock BW; Snowden JA; Shalet SM; DeRogatis LR; Ross RJ
    Cancer; 2010 Mar; 116(6):1592-601. PubMed ID: 20186765
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of a novel neoadjuvant and adjuvant hormone-deprivation approach on quality of life, voiding function, and sexual function after prostate brachytherapy.
    Miller NL; Bissonette EA; Bahnson R; Wilson J; Theodorescu D
    Cancer; 2003 Mar; 97(5):1203-10. PubMed ID: 12599226
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quality of life in long-term Hodgkin's disease survivors with chronic fatigue.
    Hjermstad MJ; Oldervoll L; Fosså SD; Holte H; Jacobsen AB; Loge JH
    Eur J Cancer; 2006 Feb; 42(3):327-33. PubMed ID: 16377179
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience.
    DiBlasio CJ; Malcolm JB; Hammett J; Wan JY; Aleman MA; Patterson AL; Wake RW; Derweesh IH
    BJU Int; 2009 Nov; 104(9):1208-14. PubMed ID: 19388987
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
    Kobayashi T; Nishizawa K; Mitsumori K
    Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Defining sexual outcomes after treatment for localized prostate carcinoma.
    Schover LR; Fouladi RT; Warneke CL; Neese L; Klein EA; Zippe C; Kupelian PA
    Cancer; 2002 Oct; 95(8):1773-85. PubMed ID: 12365027
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased prevalence of chronic fatigue among survivors of childhood cancers: a population-based study.
    Jóhannsdóttir IM; Hjermstad MJ; Moum T; Wesenberg F; Hjorth L; Schrøder H; Mört S; Jónmundsson G; Loge JH
    Pediatr Blood Cancer; 2012 Mar; 58(3):415-20. PubMed ID: 21425447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.